Do cannabinoid drugs have a therapeutic value as analgesics?

Prof Nurse

Imperial College School of Medicine, Department of Anaesthetics, Chelsea and Westminster Hospital, London.

Published: September 2002

Laboratory research has shown promising results for using plant-derived, synthetic or endogenous cannabinoids for analgesia. However, human studies are few and far between and have been held up by the law and the lack of standardised extracts. This paper considers these drugs' potential uses in pain management.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cannabinoid drugs
4
drugs therapeutic
4
therapeutic analgesics?
4
analgesics? laboratory
4
laboratory promising
4
promising plant-derived
4
plant-derived synthetic
4
synthetic endogenous
4
endogenous cannabinoids
4
cannabinoids analgesia
4

Similar Publications

Our knowledge about the consumption of cannabinoids during pregnancy lacks consistent evidence to determine whether it compromises neurodevelopment. Addressing this task is challenging and complex since pregnant women display multiple confounding factors that make it difficult to identify the real effect of cannabinoids' consumption. Recent studies shed light on this issue by using pluripotent stem cells of human origin, which can recapitulate human neurodevelopment.

View Article and Find Full Text PDF

Drug interactions in a sample of inpatients diagnosed with cannabis use disorder.

J Neural Transm (Vienna)

January 2025

Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

The majority of patients with cannabis use disorder (CUD) regularly take medication. Cannabinoids influence metabolism of some commonly prescribed drugs. However, little is known about the characteristics and frequency of potential cannabis-drug (CDIs) and drug-drug interactions (DDIs) in patients with CUD.

View Article and Find Full Text PDF

To evade legal controls, new psychoactive substances (NPS), which have been designed as substitutes for traditional and synthetic drugs, are gradually dominating the drug market. Synthetic cannabinoids (SCs), which account for the majority of NPS, are rapidly being derivatized; consequently, controlling increasing abuse by merely listing individual compounds is difficult. Therefore, China has included the entire SC category of SCs listed as legal controlled substances since July 1, 2021.

View Article and Find Full Text PDF

Background: Synthetic cannabinoids are one of the most identified abused drugs nowadays. Their popularity is due to their psychoactive effects, which resemble delta 9 tetrahydrocannabinol. This study investigates the genotoxic potential of three synthetic cannabinoids of indazole-passed drugs, AB-Fubinaca, AMBFubinaca, and EMB-Fubinaca (at a final concentration of 200 nM).

View Article and Find Full Text PDF

Products containing cannabidiol (CBD) have become increasingly popular due to consumer-perceived benefits of improving health and well-being. More specifically in the United Kingdom (UK), CBD food products are categorised as . For these products to remain on the market, they must have authorisation from the Food Standards Agency on the basis that they are safe, correctly labelled, and do not contain substances classified under controlled drugs legislation in accordance with any existing or future Home Office guidance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!